GHK-Cu affects approximately 31.2% of the human genome, influencing over 4,000 genes
Kojima M, Sun L, Hata I, Sakamoto Y, Sasaski H, Sasaki K
Swierkosz-Lenart K, Dos Santos JF, Elowe J, Clair AH, Bally JF, Riquier F, et al
In the SURMOUNT-5 trial, published in the New England Journal of Medicine, patients receiving tirzepatide had a mean percent decrease in body weight of 20.2%, compared with 13.7% for those receiving semaglutide,over 72 weeks
Common ones are mild and might include pain or redness at the injection site, mild diarrhea, or itching
Dose adjustments or therapy changes based on response and tolerability